- | X4 Pharmaceuticals
Interim Clinical Data Give Hopes for Waldenström’s Macroglobulinemia Patients
Paula Ragan, PhD, CEO and President, X4 Pharmaceuticals, discusses positive interim data from the phase 1b clinical trial (NCT04274738) evaluating mavorixafor in combination with ibrutinib in double-mutation Waldenström’s Macroglobulinemia (WM) patients.
- | Anima Biotech
Fighting Disease by Modulating the Translation of Proteins
Anima Biotech has developed a platform that allows it to use small molecule that selectively control mRNA and can decrease or increase the translation of proteins.
- | Sio Gene Therapies
Sio Gene Therapies developing CNS-targeted gene therapies
Sio Gene Therapies is pushing the boundaries of gene therapy to develop treatments for three debilitating neurodegenerative diseases, including clinical-stage product candidates in rare fatal pediatric disorders and adult Parkinson’s disease.
- | Ikena Oncology
What’s in a name? Biotech companies look to stand out from the crowd
Ikena Oncology changed its name in late 2019 after a three-month deliberation process; the company previously went by Kyn Therapeutics.
- | Windtree Therapeutics
How the U.S. Military Primed Windtree CEO Craig Fraser for C-Suite Success
Craig Fraser, CEO of Windtree Therapeutics, became a U.S. Marine at age 17, learning to perform and lead under pressure in the field before eventually leading in the C-suite.
- | OncoSec
Tumor-Agnostic Therapy for Anti-PD-1 Nonresponders
OncoSec Medical’s Tavo, a DNA-based interleukin-12 immunotherapy that is delivered to tumors via electroporation, is currently in Phase II trials
- | Scynexis
Scynexis Announces Launch Plans for Ibrexafungerp
Scynexis announced it will commercially launch its Brexafemme (ibrexafungerp) therapy in the 3rd quarter of 2021 at a media event today. The company plans a full marketing rollout for its launch in the coming months.
- | OncoSec
Outsmarting cancer with RNA, ‘genome-tuning’ drugs and other gene-altering therapies
OncoSec’s DNA-delivery system is designed to prompt the body to make more of its own IL-12. “The DNA essentially co-opts the cell’s function to cause it to make IL-12,” explained Daniel O’Connor, former CEO of OncoSec, in an interview.
